Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma - Authors' reply
- PMID: 37269849
- DOI: 10.1016/S1470-2045(23)00235-8
Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma - Authors' reply
Conflict of interest statement
CM-K declares a research grant to their institution from MSD, and an unpaid leadership role as the Scientific Secretary of the EuroNet-PHL group. JL-P declares a grant support from programme hospitalier de recherche clinique en cancerologie and participation on data monitoring committee for Bristol Myers Squibb and Boehringer. All other authors declare no competing interests.
Comment on
-
Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study.Lancet Oncol. 2023 Mar;24(3):252-261. doi: 10.1016/S1470-2045(23)00019-0. Lancet Oncol. 2023. PMID: 36858722 Clinical Trial.
-
Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma.Lancet Oncol. 2023 Jun;24(6):e230. doi: 10.1016/S1470-2045(23)00211-5. Lancet Oncol. 2023. PMID: 37269848 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
